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Abstract Von Willebrand disease (VWD) is the most
common inherited bleeding disorder with an estimated
prevalence of *1% and clinically relevant bleeding
symptoms in approximately 1:10,000 individuals. VWD is
caused by a deficiency and/or defect of von Willebrand
factor (VWF). The most common symptoms are mucocu-
taneous bleeding, hematomas, and bleeding after trauma or
surgery. For decades, treatment to prevent or treat bleeding
has consisted of desmopressin in milder cases and of
replacement therapy with plasma-derived concentrates
containing VWF and Factor VIII (FVIII) in more severe
cases. Both are usually combined with supportive therapy,
e.g. antifibrinolytic agents, and maximal hemostatic mea-
sures. Several developments such as the first recombinant
VWF concentrate, which has been recently licensed for
VWD, will make a more ‘‘personalized’’ approach to VWD
management possible. As research on new treatment
strategies for established therapies, such as population
pharmacokinetic-guided dosing of clotting factor concen-
trates, and novel treatment modalities such as aptamers and
gene therapy are ongoing, it is likely that the horizon to
tailor therapy to the individual patients’ needs will be
extended, thus, further improving the already high standard
of care in VWD in most high-resource countries.
Key Points
Von Willebrand disease (VWD) is the most common
inherited bleeding disorder and is mainly
characterized by mucocutaneous bleeding and
bleeding after trauma or surgery.
For decades, hemostatic treatment in VWD has
consisted of desmopressin and plasma-derived von
Willebrand factor (VWF)-containing concentrates.
Recently, the first recombinant VWF concentrate has
been developed and licensed for treatment of VWD
in the USA. As research on new treatment modalities
is ongoing, it is likely that management of VWD
patients can be improved further.
1 Introduction
Von Willebrand disease (VWD) is the most common
inherited bleeding disorder with an estimated prevalence of
*1% [1]. Clinically relevant bleeding symptoms are pre-
sent in approximately 1:10,000 individuals [2]. VWD is
caused by a quantitative and/or qualitative defect in von
Willebrand factor (VWF).
1.1 Function of von Willebrand Factor (VWF)
VWF plays an important role in primary hemostasis. It
circulates in the plasma in a globular, inactive form. When
vascular damage occurs, VWF binds to the exposed
& Frank W. G. Leebeek
f.leebeek@erasmusmc.nl
1 Department of Pediatric Hematology, Erasmus University
Medical Center - Sophia Children’s Hospital, Wytemaweg
80, 3015 CN Rotterdam, The Netherlands
2 Department of Hematology, Erasmus University Medical
Center, Rotterdam, ‘s-Gravendijkwal 230, 3015 CE
Rotterdam, The Netherlands
Drugs
DOI 10.1007/s40265-017-0793-2
vascular subendothelial collagen and uncoils. Once VWF is
uncoiled, the binding site for platelet glycoprotein Iba on
the VWF A1 domain becomes exposed, allowing platelets
to bind [3]. Concomitantly, platelets also bind to vascular
collagen. After activation by thrombin and other agonists,
platelets undergo shape changes and platelet integrin
aIIbb3 (the GPIIb-IIIa complex) becomes able to bind
VWF with high affinity, but also fibrinogen and fibronectin,
leading to subsequent platelet aggregation [4].
1.2 Pathophysiological Mechanisms in von
Willebrand Disease (VWD)
The function of VWF and pathophysiology of VWD is
better understood if the different phases of VWF-synthesis,
-secretion, and -clearance are taken into account.
1.2.1 Synthesis of VWF
VWF is synthesized in endothelial cells and megakary-
ocytes. The protein pre-pro-VWF is produced after primary
translation and glycosylation of mRNA by ribosomes in the
endoplasmic reticulum of endothelial cells and megakary-
ocytes. This protein includes a signal peptide, a large
propeptide and the mature VWF subunit, which is com-
posed of several structural domains, named A to D. After
cleavage of the signal peptide, the VWF subunits dimerize
and are transported into the Golgi apparatus, where disul-
fide bridges are formed between the D3 domains. This
leads to formation of VWF multimers. The propeptide is
subsequently cleaved but remains noncovalently bound to
the forming VWF multimer, facilitating the disulfide bond
formation. These ultra large VWF multimers are the most
hemostatically potent multimers [5].
1.2.2 Secretion of VWF
After synthesis, up to 95% of VWF is secreted constitu-
tively into the circulation, whereas the remainder is stored
in Weibel-Palade bodies in the endothelium, and in platelet
a-granules [6]. Adrenergic stress, thrombin generation, or
treatment with desmopressin (DDAVP) stimulates the
release of stored VWF [7]. After secretion, the ultra large
multimers are proteolyzed by ADAMTS13—a disintegrin
and metalloproteinase with a thrombospondin type 1 motif,
member 13—into smaller multimers that circulate in
plasma [8].
1.2.3 Clearance of VWF
After secretion of VWF into the circulation, the survival of
the VWF multimers depends on their size, interaction with
platelets and other cells, susceptibility to proteolysis, and
the rate of clearance from the circulation [9]. These
mechanisms of VWF clearance are not yet fully under-
stood. Abnormal clearance of VWF may also contribute to
the pathogenesis of VWD, as several gene mutations have
been identified that are specifically associated with
increased clearance of endogenous VWF [10].
1.3 Epidemiology and Diagnosis
Patients are diagnosed based on a personal or family his-
tory of bleeding and laboratory abnormalities in VWF,
Factor VIII (FVIII), or both. VWD is classified into three
types. Type 1, which accounts for 70–80% of cases, is a
partial quantitative deficiency of von Willebrand factor due
to either reduced production and/or secretion, or increased
clearance of VWF. Type 2, which accounts for approxi-
mately 20% of cases, includes several qualitative defects of
VWF defined as subtypes 2A, 2B, 2M, and 2N. Type 3
(accounting for \5% of cases) is defined as a virtually
complete absence of VWF, making this the most severe
type of VWD (Table 1) [9].
To systematically quantify the bleeding symptoms in an
individual, bleeding scores may be a helpful diagnostic tool
[11]. Different bleeding questionnaires have been devel-
oped over the years, but since 2010, the International
Society for Thrombosis and Hemostasis Bleeding Assess-
ment Tool (ISTH-BAT), intended for use in both adults and
children, is recommended [12]. This questionnaire scores
14 different bleeding symptoms on a scale of 0–4. The
values for an abnormal bleeding score are C3 in children,
C4 for adult males and C6 for adult females [13]. A lim-
itation of the score is that it is a cumulative score, which
means that the score is age dependent, can be saturated, and
that bleedings in the past may reveal a high bleeding score,
which may not reflect the current bleeding phenotype.
Key measurements in the evaluation of VWD include
VWF Ristocetin Cofactor (VWF:RCo), which measures the
ability of VWF to interact with platelets; VWF antigen
(VWF:Ag), as a measure of the total amount of VWF; and
FVIII, which reflects the ability of VWF to chaperone FVIII
through the circulation.According tomost guidelines, in order
to establish a definite diagnosis of type 1 VWD, a patient
requires VWF:RCo levels \0.30 IU/ml and a ratio of
VWF:RCo to VWF antigen (VWF:Ag)[0.6. Patients with a
bleeding tendency and VWF:RCo levels of 0.30–0.50 IU/ml
are regarded as individualswith ‘‘lowVWF levels,’’which are
considered a risk factor for bleeding [5]. Patients with type 2
VWDhaveVWF:RCo levels\0.30 IU/ml and aVWF:RCo to
VWF:Ag ratio or a FVIII toVWF:Ag ratio ofB0.60. Type 2N,
which is characterized by a reduced binding of FVIII toVWF,
shows lowFVIII levels and a reduced FVIII toVWF:Ag ratio.
A patient is diagnosed with type 3 VWD when VWF:Ag is
\0.05 IU/ml.
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1.4 Clinical presentation and Complications
The most common symptoms in VWD patients are
mucocutaneous bleedings, such as epistaxis (*50%),
oral cavity bleeding (*60%), hematomas, and bleeding
from minor wounds (*80%). In women, menorrhagia is
often present, eventually leading to iron-deficiency ane-
mia necessitating iron administration or blood transfu-
sions in some cases [14]. The risk of severe post-partum
hemorrhage is increased, especially in women with low
factor levels in the third trimester. This risk remains
higher than in healthy women, despite specialized
treatment [15]. One of the most difficult complications
to manage is gastrointestinal bleeding, which occurs
mainly in elderly type 2A and type 3 VWD patients.
Most commonly, gastrointestinal bleeding is caused by
angiodysplasia, although it is difficult to establish this
diagnosis. Joint and muscle bleeding are rare, although
these may be underestimated complications, as in a
recent study 23% of moderate and severe VWD patients
reported joint bleeding [16]. Bleeds in joints and mus-
cles are explained by the fact that VWF functions as
chaperone protein of FVIII, protecting FVIII from pro-
teolysis in the circulation. Therefore, severe deficiency
of VWF causes a concomitant deficiency of FVIII.
Patients with both a severe VWF and FVIII deficiency
may present with joint bleeds, which are more typical
for hemophilia and may cause long-term impairment.
Bleeding symptoms leading to a diagnosis of VWD
often present peri- or postoperatively or after dental pro-
cedures in index patients. When this occurs, a family his-
tory should be taken subsequently and a hemostatic work-
up should be performed evaluating both the primary and
the secondary hemostasis, and should include laboratory
evaluation of VWF and FVIII levels in order to identify
hemostatic abnormalities [11].
1.5 Inheritance and Molecular Genetics
There is a large variation in mutations described in VWD.
Quantitative deficiencies of VWF as observed in severe
type 1 and type 3 are mostly caused by null alleles (large
gene deletions, stop codons, frameshift mutations, or
splice-site mutations), but may also be caused by mutations
in the promotor regions of the VWF gene [17, 18]. Type 3
patients are usually homozygous or compound heterozy-
gous for these defects [19]. Type 1 VWD is mostly caused
by heterozygous missense mutations [17, 20, 21]. How-
ever, in approximately 30% of type 1 VWD patients, no
mutations in the VWF gene are identified [20, 21]. Type 2
VWD is characterized by missense mutations, which are
located in the affected functional domain. The inheritance
of subtypes 2A, 2B, and 2M is autosomal dominant. Type
2N VWD has a recessive inheritance pattern and is caused
by homozygosity for two type 2N mutations, or compound
heterozygosity, with a type 1 defect and a type 2N defect
[22].
1.6 Variation in VWF Levels
It is well known that even in individuals with similar gene
mutations, plasma VWF levels show a large intra- and
interindividual variability. A major determinant of
interindividual variation in VWF levels is ABO blood
group, as VWF plasma levels are approximately 25% lower
in individuals with blood group O, when compared to non-
O individuals [23]. In these individuals, an increased
clearance is described, possibly regulated by the ABO
blood group antigens on N-linked oligosaccharides of
VWF [24].
Genome-wide association studies (GWAS) have also
identified several other genetic loci that are associated with
VWF levels in healthy individuals. Mutations or poly-
Table 1 Von Willebrand disease (VWD) classification according to the International Society on Thrombosis and Hemostasis [9]
Type of VWD Description % of total VWD population (%)
1 Partial quantitative deficiency of VWF 70–80
2 Qualitative VWF defects *20
2A Decreased VWF-dependent platelet adhesion and a deficiency of high-
molecular-weight VWF multimers
2B Increased affinity for platelet glycoprotein Ib (GpIb) and a deficiency of high-
molecular-weight VWF multimers
2M Decreased VWF-dependent platelet adhesion without a deficiency of high-
molecular weight VWF multimers
2N Markedly decreased binding affinity for FVIII
3 Virtually complete deficiency of VWF \5
VWF von Willebrand factor
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morphisms in these loci may explain variability in VWF
levels between individuals with VWD but also the varying
bleeding phenotype in patients without variations or
mutations in the gene coding for VWF. C-type lectin
domain family 4 member M (CLEC4M) and Lipoprotein
Receptor 1 (LRP1) have been associated with VWF
clearance [25, 26], and Syntaxin Binding Protein 5
(STXBP5) seems to affect VWF exocytosis [27]. New
candidate genes for VWF levels found in GWAS include
SCARA5, STAB2, STX2, TC2N, and UFM1 [27, 28].
Recently, a linkage analysis identified a highly significant
quantitative trait locus (QTL) on chromosome 2 that was
not detected earlier by large GWAS. The effect size on
VWF variation of this locus was comparable to the effect
of the ABO locus (19.2 vs. 24.5%) [29]. The effect
mechanism of this genetic variant has not yet been
elucidated.
Besides these endogenous factors (blood group, gene
mutations, and modifying genetic loci), many exogenous
factors have been identified that clearly influence VWF
levels, such as physical exercise, stress, inflammation,
hypertension, diabetes, hormones, and pregnancy [30–33].
Moreover, VWF levels also increase with age, possibly
explained by increasing arterial rigidity over time [34, 35].
All these different factors lead to challenges in establishing
normal and abnormal VWF levels in individuals with and
without a clinically significant bleeding phenotype.
2 Current Treatment Options
In this review article, we aim to give an overview of cur-
rent treatment in congenital VWD. Firstly, we will discuss
treatment for acute bleeding events and how to prevent
bleeding during surgical and dental procedures (‘‘on-de-
mand’’ treatment). Secondly, we will discuss ‘‘prophylac-
tic’’ treatment, which aims to prevent spontaneous bleeding
in VWD patients who experience frequent and severe
bleeding. Furthermore, we will elaborate on novel devel-
opments and future perspectives with regard to treatment of
this frequently diagnosed bleeding disorder.
The goal of treatment inVWDpatients is to stop or prevent
bleeding by increasing plasma VWF and FVIII levels to
adequate hemostatic levels by stimulation of the release of
endogenous VWF by administration of DDAVP, or by
infusing VWF-containing factor concentrates. Choice of
treatment is dependent on the type of disease and the severity
of the bleeding. A multidisciplinary approach involving a
(pediatric) hematologist and other specialists, such as
(orthopedic) surgeon, gynecologist, anesthesiologist, or clin-
ical geneticist is of course dependent on the specific hemo-
static challenge and situation, but is of great importance to
provide optimal care for the individual VWD patient.
2.1 Desmopressin (DDAVP)
Desmopressin (1-deamino-8-d-arginine vasopressin,
DDAVP) is a synthetic vasopressin analogue. The drug
increases VWF and FVIII plasma levels by releasing VWF
from Weibel-Palade bodies in the endothelium [7]. Due to
this effect, it is the most widely used drug in the treatment
of VWD.
DDAVP can be administered intravenously or subcuta-
neously at a standardized dose of 0.3 lg/kg every 12–24 h.
Although some groups have suggested the use of a capped
dose of 15 or 20 lg, further research is warranted to prove
the effectiveness of this concept [36, 37]. DDAVP is also
available as an intranasal spray, often used for home
treatment in case of bleeding. Intranasal dosing is 150 lg
(one puff) in patients \50 kg or 300 lg (two puffs) in
patients C50 kg. Due to variable adsorption in case of
intranasal administration, an increase in VWF and FVIII
may be lower than after intravenous or subcutaneous
administration [38].
Interindividual response to DDAVP differs greatly.
Most type 1 VWD patients respond well to DDAVP. In
type 2 VWD, responsiveness to DDAVP varies signifi-
cantly and is difficult to predict. Understandably, type 3
VWD patients are unresponsive as they have little to no
endogenous VWF to mobilize. Individual characteristics
such as VWF gene mutation and baseline VWF:Ag and
VWF:RCo levels have been reported to influence the
increase of VWF and FVIII plasma levels and duration of
response [39]. In general, response in the individual patient
has been proven to be reproducible and consistent over
time [40]. However, it is important to realize that DDAVP
response decreases when DDAVP is administered
sequentially at short intervals (tachyphylaxis) due to
depletion of VWF storage in the endothelium [41].
Due to the great interpatient variability in response, a
DDAVP test is required to establish DDAVP response in
each individual patient. Different protocols dictate differ-
ent blood sampling regimens, but there is general agree-
ment that plasma levels of VWF and FVIII should be
measured prior to, and at least 1 (peak level) and 4 h after
DDAVP infusion. According to most investigators, a
patient is defined as responsive to DDAVP when VWF and
FVIII levels increase at least two- to threefold and VWF
and FVIII levels are[0.30 IU/ml 30–90 min after DDAVP
administration [42, 43]. In most patients with rapid clear-
ance of VWF, the initial response to DDAVP is substantial.
However, VWF and FVIII levels may decrease to inade-
quate levels within several hours when the half-life of
VWF and FVIII is short [44]. Therefore, whether DDAVP
is an adequate treatment option is dependent on both the
type and the severity of the bleeding or surgical procedure
as well as on the initial response and duration of response.
J. M. Heijdra et al.
In individuals with type 2B VWD, DDAVP treatment is
contraindicated because of aggravation of the tendency
towards thrombocytopenia [45].
DDAVP is considered safe but may have mild side
effects, such as flushing, transient headache, or hypoten-
sion [46]. To prevent occurrence of more severe side
effects such as hyponatremia and cardiovascular events,
fluid intake should be restricted to 1500 ml during the first
24 h after administration of the drug. This applies for
pediatric patients eligible for DDAVP with a body weight
[20 kg and adult patients without adjusting for body
weight. Due to the risk of side effects, in very young (\4
years) and older ([70 years) patients desmopressin should
be used with caution [47]. The use of DDAVP in pregnant
women also remains controversial due to the lack of evi-
dence of safety and efficacy in this group. Several cases
have been reported, describing complications such as
hyponatremia, pre-term delivery, and uterine contractions
in this patient group [48].
2.2 Plasma-Derived Factor Concentrates
Until the 1980s, patients unresponsive to DDAVP were
usually treated with cryoprecipitate. The emergence of
virally-inactivated FVIII concentrates containing VWF for
the treatment of hemophilia A proved a more optimal
therapeutic option for patients with VWD.
Those eligible for treatment with plasma-derived factor
concentrates are type 3VWDpatientswho donot produce any
endogenous VWF, and type 2B VWD patients in whom
DDAVP can cause thrombocytopenia. Furthermore, factor
concentrates are used in patients with type 1 and type 2 VWD
who are insufficiently responsive to DDAVP, or patients with
contraindications for DDAVP therapy. VWF/FVIII concen-
trates can be administered in case of bleeding or surgery, but
also as prophylaxis in severe VWD patients with recurrent
spontaneous bleeding, including joint bleeds, gastrointestinal
bleeds in the elderly, and severe epistaxis in children.
Nowadays, several plasma-derived, virally inactivated
factor concentrates containing VWF and FVIII are licensed
for treatment of VWD. However, the availability of
replacement therapy for bleeding disorders in general is
strongly dependent on the economic situation and health-
care organization in countries. As in most severe cases
VWF as well as FVIII levels are decreased, both factors
often require substitution. The different available products
contain different ratios of VWF and FVIII, with differences
in specific activity (Table 2) [49–51]. Therefore, before
treating a patient with a VWF/FVIII concentrate, the
specific activity and the VWF:RCo/VWF:Ag and
VWF:RCo/FVIII ratios should be considered.
For on-demand treatment, calculation of the required
dose of VWF or FVIII is based on the empirical finding
that 1 IU VWF:RCo per kg body weight raises VWF with
Table 2 Von Willebrand factor containing concentrates for the treatment of von Willebrand disease tested in prospective clinical studies
Product Manufacturer Preparation Purification Viral inactivation Ratio VWF:RCo/
VWF:Aga
Ratio
VWF:RCo/
FVIIIa
Alphanate Grifols PD Heparin ligand chromatography S/D ? dry heat 0.47 ± 0.1 0.91 ± 0.2
Factor 8Y Bioproducts
Laboratory
PD Heparin/glycine precipitation S/D ? dry heat 0.29 0.81
Fanhdi Grifols PD Heparin ligand chromatography S/D ? dry heat 0.47 ± 0.1 1.04 ± 0.1
Humate-P
(US)
Haemate P
(EU)
CSL Behring PD Multiple precipitation Pasteurization 0.59 ± 0.1 2.45 ± 0.3
Immunate Shire PD Ion-exchange chromatography S/D ? vapor heat 0.47 1.1
Koate-
DVI
Kedrion
Biopharma
PD Multiple precipitation ? size
exclusion chromatography
S/D ? dry heat 0.48 1.1
Voncento CSL Behring PD Heparin/glycine precipitation
? gel filtration chromatography
S/D? dry heat 0.87–0.95 2.0
Vonvendi Shire Rec – – [1 [10
Wilate Octapharma PD Ion-exchange ? size exclusion
chromatography
S/D ? dry heat – 0.9
Wilfactin LFB PD Ion-exchange ? affinity
chromatography
S/D ? nanofiltration
? dry heat
0.7 60
PD plasma derived, Rec recombinant, S/D solvent detergent
a Data derived from [49–51]
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*1.5% and 1 IU FVIII:C per kg raises FVIII plasma level
by*2%. Dosing is based on both VWF:RCo and FVIII:C
levels. The aim is to increase or normalize both factor
levels in order to ensure adequate hemostasis. The more
recent applicability of quickly available results of
VWF:RCo or VWF:GPIbM assays has greatly improved
and facilitated VWF/FVIII concentrate dosing [52].
In case of treatment with bolus infusions, the required
dose is determined using the following formula: Required
IU of VWF concentrate (based on VWF:RCo con-
tent) = body weight (kg) 9 desired VWF:RCo rise (%)
(IU/dl)/1.5. In case of continuous infusion, the initial
infusion rate is calculated as follows: Infusion rate (IU/kg/
h) = clearance (ml/kg/h) 9 desired steady state level (IU/
ml). Continuous infusion is feasible, as Lubetsky et al.
described that in their study, reconstituted Humate P was
stable for 14 days at room temperature [53].
In principle, the endogenous FVIII synthesis in VWD
patients is normal. The low FVIII plasma concentrations
are the result of low VWF and/or decreased binding affinity
of VWF for FVIII. When exogenous VWF is infused, it
binds and stabilizes FVIII, thereby increasing the FVIII
plasma level. Furthermore, clearance of FVIII is known to
be lower than that of VWF [54]. Subsequently, VWF/FVIII
concentrate infusions in a short time period may lead to
very high FVIII:C plasma concentrations ([2.70 IU/ml),
and thus form a possible risk factor for thromboembolic
complications [55–57]. Therefore, daily measurements of
plasma FVIII levels after surgery are important in patients
receiving repeated doses of VWF/FVIII concentrate not
only to assess the risk of bleeding but also to monitor the
risk of thrombosis. The terminal half-life of VWF:Ag and
VWF:RCo differs greatly between patients [58]. Monitor-
ing of VWF:RCo levels intraoperatively and during the
first postoperative days is important to determine timing
and dosing of the follow-up bolus infusions to ensure
hemostatically adequate levels of VWF in the first phases
of wound healing (Table 3) [1, 14, 52, 59]. For a treatment
algorithm for bleeding and dental and surgical procedures
with VWF/FVIII concentrates according to the National
Heart, Lung and Blood Institute (NHLBI), see Fig. 1.
In theory, a product with a VWF/FVIII ratio of
approximately 1:1 is the easiest to dose, because the rise of
VWF and FVIII plasma levels after infusion can be easily
predicted [60, 61]. However, although no randomized trials
have been performed, all different products with different
ratios show good to excellent hemostatic properties in
observational clinical studies [62, 63]. Moreover, there is
broad clinical experience in treatment of VWD patients
with Humate-P—the first virus-inactivated VWF/FVIII
concentrate—which has been on the market for more than
30 years [64].
The rationale for treatment with highly purified con-
centrates containing nearly no FVIII or treatment with
recombinant VWF is that patients with VWD all have
normal production of FVIII, but lack adequate VWF levels
to protect FVIII from degradation. When VWF levels are
normalized by infusion of exogenous VWF, a subsequent
rise of endogenous FVIII is expected. However, the rise of
FVIII after infusion is slow and a peak is achieved only
after 6–8 h [65]. Therefore, patients with low circulating
FVIII levels require a priming dose of FVIII in addition to
the VWF concentrate when hemostasis needs to be cor-
rected promptly. In case of elective surgery, a VWF con-
centrate infusion should be administered at least 6–8 h
before the operation to allow FVIII to rise to adequate
levels in time for the procedure when no additional FVIII is
administered.
Table 3 Recommendations for FVIII and von Willebrand factor (VWF) target levels in minor and major surgical and dental procedures
according to a selection of guidelines
Guideline Minor procedures Major procedures
FVIII target levels
(IU/ml)
VWF:RCo target
levels (IU/ml)
Duration
(days)
FVIII target levels
(IU/ml)
VWF:RCo target
levels (IU/ml)
Duration
(days)
NHLBI (US) [1] nd
[0.50
[1.00
[0.50
Perioperative
3–5
nd
[0.50
[1.00
[0.50
Perioperative
7–14
AICE (Italy) [59] [0.30 nd 2–4 [0.50 nd 5–10
NVHB (the
Netherlands) [14]
[0.80
[0.50
[0.30
[0.80
nd
nd
Perioperative
3
4–7
[0.80
[0.50
[0.80
nd
Perioperative
7–10
UKHCDO (UK) [52] [0.50 [0.50 nd C1.00
[0.50
nd
[0.50
Perioperative
6–10
NHLBI National Heart, Lung and Blood Institute, AICE The Italian Association of Hemophilia Treatment Centers, NVHB Dutch Society for
Hemophilia Treaters, UKHCDO United Kingdom Haemophilia Centre Doctors’ Organisation, nd not defined in guidelines
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2.3 Treatment in Patients with Alloantibodies
Alloantibodies against VWF are a rare complication in
VWD, with an estimated prevalence of 6–10% in type 3
VWD patients [66, 67]. Almost all cases occur in type 3
VWD patients with partial or complete VWF gene dele-
tions [68, 69], although a case of alloantibodies in a type
2B VWD patient has recently been described [70].
Patients with antibodies against VWF generally present
with an impaired response to infused VWF-containing
concentrates. When re-exposed to VWF, some patients—
especially those with high-titer alloantibodies—may
develop severe anaphylactic reactions [71, 72]. Recombi-
nant FVIII has been used successfully for hemostatic
therapy in patients with anti-VWF antibodies. Due to the
lack of stabilization by VWF, the half-life of FVIII is
decreased. This problem can be overcome by continuous
infusion of higher doses of FVIII concentrate [67]. Another
option is treatment with recombinant Factor VIIa (rFVIIa)
or activated prothrombin complex, which functions as a
FVIII and Factor IX (FIX) bypassing agent [73–75]. These
are regularly used to treat hemophilia patients with
inhibiting antibodies. To extrapolate this experience to
VWD patients with inhibiting antibodies seems reasonable,
but sparse evidence for effectiveness and safety of rFVIIa
treatment in patients with anti-VWF antibodies requires
caution with regard to these products.
Immune tolerance induction (ITI) therapy, using high
doses of factor concentrates and immunosuppressive ther-
apy, is widely applied in hemophilia A. A case report of a
20-year-old male with alloantibodies to VWF treated with
ITI was published in 2012. After 3 years of ITI treatment,
inhibiting antibodies could still not be detected anymore,
but the half-life of VWF-containing concentrates did not
normalize [76]. Therefore, on the basis of this sporadic
evidence, more research is required to assess safety and
efficacy of ITI in VWD patients, especially as anaphylactic
reactions may occur in this setting.
2.4 Recombinant VWF Concentrate
For patients with hemophilia, recombinant coagulation
factor concentrates have been available for nearly two
decades. These products reduce the transfer risk of viral
infections and potentially other infectious agents. Another
advantage is the independence of donor availability for the
supply of plasma-derived concentrates. For VWD, Turecek
and co-workers have recently developed a recombinant
VWF (Vonicog alfa, rVWF) that is produced in genetically
altered CHO cells expressing both VWF and FVIII [77]. As
VWF is synthesized in the absence of the VWF protease
ADAMTS13, this rVWF contains intact high molecular
weight and ultra large multimers, resulting in a higher
specific activity (ratio VWF:RCo:VWF:Ag[1.0) than in
plasma-derived VWF concentrate. In 2013 Mannucci et al.
reported a phase 1 trial to study the pharmacokinetic
parameters of this product. The terminal half-life of of
rVWF was comparable to that of plasma-derived VWF
[78]. In a recent phase 3 clinical study on the treatment of
bleeding episodes in patients with severe type1, 2, or 3
VWD, rVWF showed a high efficacy in cessation of
bleeding [79]. The first dose of rVWF was administered
together with rFVIII and subsequently without rFVIII. The
outcome of treatment was rated as excellent in over 96% of
bleeding episodes. Additional pharmacokinetic studies
showed that FVIII normalized after sole infusion of rVWF
within 6 h. Treatment was considered safe, as no throm-
bosis, allergic reactions, or development of inhibitors to
rVWF were demonstrated. Currently, studies are ongoing
on the efficacy of rVWF in surgery, as well as studies on
the use of long-term prophylaxis with rVWF concentrate in
patients suffering from recurrent bleeding. Recently rVWF
Fig. 1 Treatment of bleeding and dental and surgical procedures with VWF/FVIII concentrate according to National Heart, Lung and Blood
Institute (NHLBI) [1]
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has been registered and approved for clinical use in the
USA for the treatment of bleedings in adults with VWD.
2.5 Supportive Treatment
2.5.1 Antifibrinolytic Agents
Antifibrinolytic agents such as tranexamic acid and ami-
nocaproic acid inhibit the interaction of plasminogen with
fibrin, thus preventing the degradation of the fibrin clot.
These agents are especially effective in the mucosa due to
the high fibrinolytic activity present in these tissues [80].
Therefore, in case of mucocutaneous bleeding, supportive
treatment with antifibrinolytics is strongly recommended in
the light of the low cost and few side effects. The hemo-
static effectiveness of tranexamic acid has also been
demonstrated in large placebo-controlled randomized trials
in patients undergoing high-risk cardiac or orthopedic
surgery [81–83]. In patients with bleeding disorders
undergoing surgical or dental procedures, antifibrinolytics
are widely used to prevent perioperative blood loss.
Although evidence from randomized controls is lacking for
efficacy in VWD, this is generally accepted to be likely
[84].
Antifibrinolytic agents can be administered systemically
as an oral or intravenous formulation, or topically, as a
mouthwash (for available formulations, concentrations, and
dose see Table 4). Importantly, hematuria of unknown
origin or caused by renal or ureteral bleeding is a con-
traindication for antifibrinolytic treatment as treatment of
blood loss in the urinary tract may lead to clotting in the
ureters and subsequent painful colic episodes with risk of
ureter obstruction [85, 86].
2.5.2 Hormonal Treatment
Menorrhagia is a very common symptom in women with
VWD, with a prevalence of 62–81% [87–89]. In women
with VWD presenting with menorrhagia, it is important to
first rule out anatomic and hormonal causes. Thereafter,
hormonal treatment with oral contraceptives containing
both progestin and estrogen can be initiated if there is no
wish for pregnancy. Oral contraceptive treatment leading to
non-ovulatory bleeding will significantly reduce uterine
blood loss during the oral contraception-free week. When
administered continuously (C28 days), total bleeding days
can be reduced drastically [90].
Another hormonal treatment option is the levonorgestrel
intrauterine device (IUD). This device suppresses endo-
metrium and spiral arteriole growth and increases capillary
thrombosis. It also has no effect on endometrial FVIII
activity, while copper-containing intrauterine devices have
been described to decrease FVIII activity [91]. In a study in
16 women with bleeding disorders receiving a levo-
norgestrel IUD, nine women became amenorrhoeic, and
the remaining seven reported a significant decrease in
menstrual blood loss [92]. Bleeding complications did not
occur at the time of insertion of the device in the presence
of adequate hemostatic or replacement therapy.
In women with menorrhagia, often a combination of
antifibrinolytic and hormonal therapy is used. Despite the
fact that the combination of tranexamic acid and oral
Table 4 Antifibrinolytic agents for the treatment of von Willebrand disease
Formulation Available
concentration
Dosea
Tranexamic acid
intravenous
10 mg/ml 0.5–1 g, 2–3x daily (1 ml/min)
Children C1 year: 20 mg/kg/day in 2–3 doses a day
Tranexamic acid oral 650 mg (US)
500 mg (EU)
0.5–1 g in 2–4 doses a day
Children C1 year: 20 mg/kg/day, in 2–3 doses a day
Tranexamic acid
mouth rinse
50 mg/ml 0.5–1.5 g (15–25 mg/kg), in 2–3 doses a day ‘‘swish and swallow or spit’’
Children C1 year: 20 mg/kg/day, in 2–3 doses a day
Aminocaproic acid
intravenous
250 mg/ml Starting dose: 4–5 g slowly during the first hour, followed by continuous infusion of 1 g/h
Children: 100 mg/kg or 3 g/m2 slowly ([1 h), followed by continuous infusion of 33.3 mg/kg/h or 1
g/m2/h
Aminocaproic acid
oral
500 mg and
1000 mg
Starting dose: 4–5 g, followed by 1–1.25 g/h or 4–6 g every 4–6 h, with a max. dose of 24 g/day
Children: starting 100 mg/kg, followed by 3 g/m2 during the first hour, followed by 33.3 mg/kg or 1
g/m2 every hour. Max. dose: 18 g/m2/day or 600 mg/kg/day
Aminocaproic acid
mouth rinse
250 mg/ml Starting dose: 4–5 g, followed by 1–1.25 g/h, with a max. dose of 24 g/day ‘‘swish and swallow or
spit’’
Children: starting 100 mg/kg, followed by 3 g/m2 during the first hour, followed by 33.3 mg/kg or 1
g/m2 every hour. Max. dose: 18 g/m2/day or 600 mg/kg/day
a Data derived from [84]
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contraceptives may be pro-thrombotic, no reports of
thromboembolic events in women with VWD using this
combination of medication have been reported. Therefore,
it is assumed that a combination of antifibrinolytic and
hormonal therapy is safe [93]. For all treatment options in
women with menorrhagia, see the treatment algorithm in
Fig. 2 [94].
2.5.3 Additional Measures
In case of epistaxis, xylometazoline nose drops can be
applied intranasally to induce vasoconstriction. When the
active bleeding focus can be identified, chemical or elec-
trical cauterization performed by an emergency- or ear,
nose, and throat physician is the preferred method of
treatment [95]. In addition, to prevent bleeding after sur-
gical or dental procedures, secure suturing is important to
achieve local hemostasis. Additional measures for wound
sealing and promotion of wound healing include applica-
tion of (autologous) fibrin glue or platelet-rich clots
[96, 97].
2.6 Management of Pregnancy and Delivery
In case of pregnancy in a VWD patient, a hematologist
should be consulted in the first trimester in order to
coordinate treatment for pregnancy and delivery if nec-
essary. In VWD type 1 and 2, VWF:Ag, VWF:RCo, and
FVIII:C should be monitored at 12 weeks and 30–34
weeks. If VWF and FVIII levels are inadequate (\0.50
U/ml) at 30–34 weeks, a multidisciplinary team con-
sisting of a hematologist, pediatric hematologist, gyne-
cologist, and anesthesiologist with expertise in bleeding
disorders should establish a treatment plan that includes
timing and dosing of factor concentrate and/or antifib-
rinolytic agent administration during childbed and hos-
pitalization as well as mode of (regional) anesthesia and
indication for atraumatic delivery. In case of post-partum
hemorrhage, factor concentrate should be administered,
taking possible other obstetric causes of bleeding into
account [98]. When good responsiveness to DDAVP has
been demonstrated prior to the event, DDAVP can be
administered after clamping of the umbilical cord.
Because of the decrease of VWF and FVIII to pre-ex-
istent levels after delivery [99], it is recommended to
supply tranexamic acid four times a day at 500–1000 mg
or aminocaproic acid 4–6 g every 4–6 h orally during the
first 7 days post-partum.
Generally, in type 1 VWD, VWF and FVIII levels
generally rise to relatively normal values in the third tri-
mester and maternal problems are not expected during
delivery. Historically, guidelines consistently have advised
to aim for target levels of VWF and FVIII [0.50 U/ml
before delivery [1]. However, Szecsi et al. reported that in
normal pregnancies FVIII:C at 38–42 weeks was
130–430% (n = 73) [100]. This fact, combined with the
observation that the risk of post-partum hemorrhage
despite specialized care is greater in women with VWD,
means it is likely that women may be ‘‘undertreated’’
currently at the time of delivery [15, 98].
Fig. 2 Treatment of menorrhagia [94]
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To determine the indication for an atraumatic delivery,
invasive prenatal diagnostic procedures can be performed
in weeks 33–34 of the pregnancy if the causative VWF
gene mutation is known. If maternal FVIII and/or VWF is
\0.50 IU/ml, treatment with factor concentrate is indicated
during such procedures. When a child with (potentially)
type 3 VWD or a clinically severe type 1 or 2 VWD is due
to be born, an atraumatic delivery should be pursued.
Vaginal delivery is usually preferred. Only in cases of
severe emergency should a forceps delivery be performed
(no vacuum extraction) and no vaginal breech delivery and
no expulsion for [1 h are to be allowed. A caesarean
section should be performed without hesitation under
adequate replacement therapy when complications are
expected. Fetal scalp blood testing and placement of a fetal
scalp electrode should be avoided. VWF and FVIII cord
blood analysis to diagnose the newborn is only indicated in
severe types 1 and 2 and in type 3 VWD. Due to relatively
high VWF and FVIII levels directly after birth due to
activation in cord blood, measurement of VWF and FVIII
in milder cases should be repeated a few weeks after birth
if results are dubious [101]. Intramuscular injections in the
neonate should be avoided or replaced by subcutaneous
injection as long as VWF and FVIII levels are unknown. In
case of a (possible) severe VWD (VWF\0.05 U/ml and/or
FVIII\0.05 U/ml), observation of the neonate during the
first 24 h is indicated. Routine ultrasound screening is not
recommended in neonates with type 3 VWD, but should be
performed consequently and rapidly when additional
bleeding risks are present or clinical symptoms suggesting
intracranial bleeding are observed. When ultrasound is not
acutely available, replacement therapy should be given
prior to imaging when symptoms are most suspect.
2.7 Treatment of Angiodysplasia-Related
Gastrointestinal Bleeding
Gastrointestinal bleeding is a common and sometimes life-
threatening problem in VWD patients, with a prevalence of
11–27%, depending on disease type [14]. In patients
lacking high-molecular weight (HMW) VWF multimers—
as in VWD type 2A—angiodysplastic lesions are often
found to be causative [102]. In vitro and in vivo studies
have identified VWF as a regulator of angiogenesis through
different pathways, although the exact mechanisms remain
unclear [103]. Identification of angiodysplasia is often
difficult. The diagnostic approach starts with endoscopy;
however, in a substantial proportion of cases results are
negative, especially when the lesions are small and not
abundant. Additional methods include video capsule
endoscopy, helical computed tomography and angiogra-
phy. Often repetitive investigations are necessary to ulti-
mately diagnose angiodysplasia [104]. Therefore, it is
important to repeat diagnostic procedures in VWD patients
presenting with unexplained iron-deficient anemia or clin-
ical symptoms of gastrointestinal bleeding, especially in
those lacking HMW VWF multimers.
In most patients with congenital VWD, replacement
therapy with factor concentrates is sufficient, but often
seems to be less effective than in other types of bleeding
[102, 105]. Several other pharmacological therapies have
been proposed for the often complex management of
recurrent gastrointestinal bleeding due to angiodysplasia. A
problem with these therapies is that effectiveness has only
been described in small case series and case reports, with
variable results. It is also likely that there is a significant
publication bias, as reports of successful pharmacologic
treatment are more likely to be published than unsuccessful
ones. As a consequence, these drugs have not yet been
approved for treatment of angiodysplasia and are currently
only prescribed off-label. Therefore, further studies on
potentially effective pharmacologic agents are required.
2.7.1 Octreotide
Treatment with octreotide, a somatostatin analogue, has
shown high efficacy and safety in studies involving non-VWD
patients with chronic bleeding due to angiodysplasia.
Regretfully, these studies included relatively small numbers
of patients and differed greatly in drug dosage and route and
duration of administration of the drug. Also, follow-up time
was relatively short [106]. In the literature, three cases of
VWD patients treated with octreotide have been described. A
case series of two VWD patients with massive and prolonged
gastrointestinal bleeding resistant to conventional treatment
was described by Bowers [107]. A rise in baseline VWF:Act
and hemoglobin was observed after initial intravenous
administration and continued subcutaneous administration of
octreotide and no hospital admissions were required during
follow-up. In 2005, Krikis et al. reported on a case of a VWD
patient with recurrent and life-threatening gastrointestinal
bleeding. This patient was treated with octreotide long-acting
release (LAR) 20mg by intramuscular injection once amonth
and propranolol 20 mg three times a day. During follow-up,
the patient experienced no bleeding. Laboratory evaluations,
however, showed no rise in VWF levels [108].
2.7.2 Thalidomide
Thalidomide inhibits angiogenesis by suppression of vas-
cular endothelial growth factor (VEGF) [109], making it an
interesting drug candidate for the treatment of angiodys-
plasia. In a literature review, Engelen et al. described 19
relevant publications on thalidomide use in angiodysplasia-
related gastrointestinal bleeding [110]. These articles
included one randomized controlled trial, two prospective
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cohort studies, seven case series, and 14 case reports. A total
of 115 patients receiving thalidomide were described. Dos-
ing ranged from 50 to 400 mg/day, with an average dose of
100 mg/day. In all studies, a beneficial effect of thalidomide
was shown as in only two of the cases thalidomide treatment
had no effect on gastrointestinal bleeding. Four out of the
total reported patients had congenital VWD. In all VWD
patients, treatment with thalidomide was successful and
bleeding episodes stopped. In one patient this effect was
temporary and the dose needed to be increased. In 17 out of
the total of 115 patients, thalidomide was withdrawn due to
side effects. Although the results of thalidomide therapy are
promising, severe side effects such as neurotoxicity and
concerns about possible oncogenetic properties limit the use
of thalidomide as long-term therapy.
2.7.3 Lenalidomide
Lenalidomide is a thalidomide analog that also has an
antiangiogenic effect, but with a somewhat more favorable
adverse effects pattern. A retrospective chart review of five
VWD patients with angiodysplasia receiving lenalidomide
was performed in 2013 by Kohli et al. [111]. Patients
received a starting dose of 5 mg daily. In one patient, it was
necessary to increase the dosage up to 15 mg daily due to
recurrent gastrointestinal bleeding. Mean bleed-free dura-
tion was 1 year and the number of endoscopies was sig-
nificantly lower after treatment. Fatigue was the most
commonly reported side effect and one patient even dis-
continued treatment due to excessive fatigue.
2.7.4 Statins
Statins in high doses have been reported to inhibit angio-
genesis [112]. In 2008, Sohal and Laffan reported a severe
type 1 VWD patient with refractory bleeding due to
angiodysplasia in the gastrointestinal tract [113]. Atorvas-
tatin was administered at 10 mg daily, with dose escalation
to 40 mg/day over the following 3 months. During 6
months of follow-up, bleeding gradually subsided and no
side effects were reported. Following this report, Alikhan
and Keeling reported on a type 2A VWD patient in whom
10 mg atorvastatin was commenced daily, increasing the
dose to 40 mg daily over 4 months [114]. A reduction in
blood transfusions was observed. After a dose increase to
80 mg, the patient had not needed any blood transfusions or
hospitalization over a follow-up period of 9 months. No
side effects were reported.
2.7.5 Hormonal and Antihormonal Therapy
Estrogen and progesterone have been investigated in a
number of studies in non-VWD angiodysplasia patients.
This mode of therapy has shown no beneficial effect and is
no longer recommended in gastrointestinal angiodysplasia
[115]. In recent years, tamoxifen has been identified as an
effective therapy for the management of patients with
hereditary hemorrhagic telangiectasia having recurrent
bleeds [116]. The counterintuitive benefits of an antie-
strogen for treating telangiectasia were noted by chance. It
is hypothesized that when estrogen binds to its receptors, it
induces proliferation of the blood vessels, and thus
telangiectatic lesions [117]. A case report by Thachil on
two VWD patients with angiodysplasia was published in
2013. In one patient, an immediate reduction of bleeding
episodes was observed, and bleeding stopped completely
after 3 months of tamoxifen treatment and persisted during
the 14-month follow-up period. The other patient discon-
tinued treatment after 4 months due to vaginal discharge.
Six months after cessation of treatment in this patient, no
further bleeds had occurred and no angiodysplastic lesions
were observed during endoscopy.
2.7.6 Danazol
Danazol has been shown to increase FVIII levels and
reduce bleeding frequency in hemophilia A patients [118].
Other studies, however, could not reproduce these findings
[119]. Therefore, the effect is thought to likely be more at
the endothelial level, rather than the result of increased
coagulation factor levels. The only study of danazol in
angiodysplasia has been performed by Botero et al. [120].
Three VWD patients with refractory gastrointestinal
bleeding were reported who were receiving danazol
100–500 mg daily. One patient experienced two transfu-
sion-free periods of 6 months almost directly after starting
danazol. The other patients needed 6 months–3 years to
achieve transfusion independence. In all patients, con-
comitant endoscopic management was still required. In one
patient, danazol had to be discontinued due to drug-induced
liver toxicity.
2.8 Prophylactic Prevention of Bleeding
Severely affected VWD patients who suffer from recurrent
bleeding episodes may be treated with VWF concentrates
two or three times a week in order to prevent bleeding
(prophylaxis). Several retrospective case series of VWD
patients on prophylaxis reported beneficial results
[121, 122]. So far only one prospective dose-escalating
study has been performed to evaluate the use of prophy-
laxis in type 1, 2, and 3 VWD patients with a severe
bleeding phenotype. A major reduction of the number of
bleedings, such as recurrent gastrointestinal bleeding and
joint bleeding or severe epistaxis was shown. Nearly all
patients required 50 VWF:RCo IU/kg two or three times a
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week. This study shows that bleeding may be reduced in
patients by regular VWF concentrate administration,
although the study was limited by slow and limited inclu-
sion of patients (total number included 12) [123]. In a
related comment on the article by Abshire et al., Federici
proposed that patients with severe VWD, irrespective of
type of VWD, who suffer from recurrent bleedings may
benefit from prophylaxis, and this option must be discussed
and offered to patients with a severe bleeding phenotype
[124].
3 Emerging Therapies in VWD
Treatment for VWD has not evolved much over the last
decades. For years, the only option for VWD patients
unresponsive to desmopressin was treatment with plasma-
derived factor concentrates. These products are effective in
the prevention and treatment of bleeding in VWD, but
adverse events such as allergic reactions and thrombosis
have been reported [57, 125]. In addition, possible trans-
mission of viral or prion diseases remains a concern in
products derived from donor plasma, although this has not
occurred for a long time due to deployment of viral inac-
tivation technologies. Meanwhile in hemophilia, treatment
with recombinant factor concentrates has already been an
established therapy for many years, and treatment with
extended half-life products are a promising solution for
current prophylaxis limitations. Here we discuss possible
future options for better and more personalized treatment in
VWD.
3.1 Individualized Management Based
on Population Pharmacokinetic Modeling
Currently, VWF/FVIII concentrate is dosed according to
body weight, type, and location of bleeding while aiming
for certain VWF and FVIII target levels. Postoperatively,
dosing is based on these parameters, but also on a crude
approximation of clearance of VWF/FVIII concentrate in
case of continuous dosing or crude half-life estimations in
case of bolus infusions.
DDAVP is administered in a standardized dose of 0.3
lg/kg intravenously every 12–24 h. When administered
sequentially in short intervals, tachyphylaxis occurs due to
depletion of the VWF storage in the endothelium.
In both of the above-mentioned treatment strategies,
other individual patient characteristics, such as age, lean
body mass, liver and kidney function, and baseline VWF
and FVIII plasma levels are not taken into account. Fur-
thermore, scarce data is available on the pharmacokinetics
(PK) of VWF/FVIII concentrate during surgery and no
population PK-models have been constructed [126, 127].
Moreover, in patients with a partial deficiency of VWF and
FVIII, the rise of these clotting factors during stress due to
interactions with the vascular endothelium remains to be
elucidated. A population PK model based on both DDAVP
and factor concentrate administration may prove valuable
in bleeding disorders such as VWD, as it has been for
dosing regimens in hemophilia A [128]. By taking indi-
vidual clearance differences into account as well as mod-
elling the interaction with the vascular endothelium in the
different VWD types, treatment can be more tailored to the
individual requirements of the patient.
3.2 Interleukin-11
Early studies in wild type mice and VWD mouse models
showed that interleukin-11 (IL-11) significantly increases
plasma VWF. Mice treated with subcutaneous IL-11 for 7
consecutive days had a twofold increase of FVIII and
VWF. In 2008, Ragni et al. reported a phase II prospective
trial in nine patients with mild VWD using different
dosages of rIL-11 given subcutaneously for 7 days. This
resulted in a 1.5- to threefold increase over baseline.
Because platelet mRNA expression increased, they sug-
gested that the mechanism of effect of rIL-11 was the
upregulation of VWF mRNA [129]. In additional clinical
studies the same group showed that menstrual bleeding
severity could be reduced by rIL-11 in patients with mild
VWD and refractory menorrhagia [130]. More recently it
was also shown that in patients with mild or moderate
VWD, who were unresponsive to DDAVP, rIL-11
increased FVIII and VWF nearly twofold [131].
3.3 Aptamers
Aptamers are a new class of oligonucleotide-based drugs
that are able to block various proteins. ARC1779 is an
aptamer that binds to the A1 domain of VWF, thereby
blocking the interaction with platelet GpIb. Animal studies
have shown that this aptamer blocks thrombus formation.
In humans this aptamer was studied in patients with type
2B VWD. This type of VWD is characterized by increased
binding of the A1 domain to the GpIb receptor on platelets.
In patients treated with DDAVP, the rise of VWF in plasma
is accompanied by thrombocytopenia, due to platelet
aggregation. The aptamer ARC1779 was able to reduce the
platelet drop after DDAVP treatment, and increased
VWF:Ag and VWF:RCo [132, 133]. Therefore it is sug-
gested that the aptamer can be used as an antibleeding drug
in VWD patients [134]. Another potential application can
be the use of the aptamer in VWD type 2B patients with
hepatitis C and thrombocytopenia. The aptamer may be
able to raise platelet counts, making these patients eligible
for interferon therapy [133]. Blockade of VWF by a longer
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acting aptamer with subcutaneous bioavailability such as
ARC15105 could potentially be useful [133]. However, no
clinical trials have been performed to determine efficacy.
3.4 Gene Therapy
In recent years several advances have been reported using
gene therapy in congenital bleeding disorders, especially in
hemophilia B. Severely affected hemophilia B patients
(FIX\1%) treated with adeno-associated virus 8 (AAV8)-
mediated gene transfer with a codon-optimized wild type
FIX gene showed FIX levels up to 5–8% of normal and
reported a strong reduction in bleeding and exogenous FIX
concentrate use [135, 136].
Gene therapy in VWD is challenging due to the large
size of the VWF gene, leading to difficulties in inserting
VWF cDNA in most viral gene transfer vectors. For VWD,
preliminary gene therapy mice studies have been reported.
De Meyer et al. used a mouse model to study liver-specific
gene transfer of murine VWF expressing vector by
hydrodynamic injection. They showed a temporary
expression of VWF by the liver, resulting in VWF levels
and consequent restoration of in vivo platelet adhesion and
aggregation [137]. Furthermore, Wang et al. showed in a
mouse model that lentiviral vectors could transfer intact
murine VWF cDNA in vivo directly to the neonatal liver of
VWF knockout mice. This resulted in production of VWF
multimers and a partial correction of VWF levels in 33% of
the treated mice [138]. Although these results seem
promising, further improvements in efficiency are needed
before clinical application is within reach.
4 Conclusion
Over the last decades, treatment of VWD has mainly been
based on DDAVP and plasma-derived factor concentrates.
With the US Food and Drug Administration approval of the
first recombinant VWF concentrate for treatment of
bleeding in VWD patients in 2015, treatment options for
VWD are now finally being expanded. As research on
pathophysiology of VWD and on new treatment modalities
is ongoing, it is likely that in the upcoming years the
options to tailor treatment to individual patient needs will
improve.
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